Dentistry Medical News about Mucositis

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Mucositis: The impact, biology and therapeutic opportunities of oral mucositis
Oral Oncology , 10/21/09

Sonis ST – While the FDA’s approval of palifermin in 2004 was limited to only a small percentage of the at–risk population, the fact that the first registered anti–OM agent derived its efficacy from its pleotropic activities was conceptually demonstrative of the therapeutic potential of drugs that selectively interfere with mucositis’ pathogenesis. A number of eclectic molecules, all designed to interfere with pathways that lead to injury are in pre–clinical and clinical development.

<< Previous
Saliva as a tool for oral cancer diagnosis and prognosis

Next >>
Effect of Implants on Maximum Bite Force in Edentulous Patients

Explorative study on the predictive value of systematic inflammatory and metabolic markers on weight loss in head and neck cancer patients undergoing radiotherapy
Supportive Care in Cancer, 10/20/09 Relevance Score: 82%

Effect of topical morphine (mouthwash) on oral pain due to chemotherapy- and/or radiotherapy-induced mucositis: a randomized double-blinded study
Journal of Palliative Medicine, 10/19/09 Relevance Score: 82%

Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP
Medical Oncology, 10/06/09 Relevance Score: 80%

Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial
The Lancet Oncology - Online First, 10/30/09 Relevance Score: 77%

Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer
Cancer Chemotherapy and Pharmacology, 10/21/09 Relevance Score: 77%